468 related articles for article (PubMed ID: 25470094)
1. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
[TBL] [Abstract][Full Text] [Related]
3. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Mathews M; Gommoll C; Chen D; Nunez R; Khan A
Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
[TBL] [Abstract][Full Text] [Related]
5. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
Jain R; Chen D; Edwards J; Mathews M
Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
[TBL] [Abstract][Full Text] [Related]
6. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
8. Vilazodone: in major depressive disorder.
Frampton JE
CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.
Durgam S; Chen C; Migliore R; Prakash C; Edwards J; Findling RL
Paediatr Drugs; 2018 Aug; 20(4):353-363. PubMed ID: 29633166
[TBL] [Abstract][Full Text] [Related]
10. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
[TBL] [Abstract][Full Text] [Related]
13. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
[TBL] [Abstract][Full Text] [Related]
14. An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.
Rele S; Millet R; Kim S; Paik JW; Kim S; Masand PS; Patkar AA
Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693034
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
16. The effect of vilazodone on sexual function during the treatment of major depressive disorder.
Clayton AH; Kennedy SH; Edwards JB; Gallipoli S; Reed CR
J Sex Med; 2013 Oct; 10(10):2465-76. PubMed ID: 23216998
[TBL] [Abstract][Full Text] [Related]
17. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
Robinson DS; Kajdasz DK; Gallipoli S; Whalen H; Wamil A; Reed CR
J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
[TBL] [Abstract][Full Text] [Related]
18. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
19. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
Khan A; Sambunaris A; Edwards J; Ruth A; Robinson DS
Int Clin Psychopharmacol; 2014 Mar; 29(2):86-92. PubMed ID: 24247740
[TBL] [Abstract][Full Text] [Related]
20. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study.
Edwards J; Sperry V; Adams MH; Gallipoli S; Thorn MD; Longstreth J; Boinpally R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):456-65. PubMed ID: 23611569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
